TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06565260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear an activity tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Participate in nutrition program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05226845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prescribed exercise
Description: the therapist chooses the five exercises to do

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chosen exercise
Description: the patient chooses the five exercises to perform among fifteen possibilities
Study: NCT05675917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MacuTest platform
Description: The MacuTest platform will be used to collect the data needed to predict AMD risk. AMD risk prediction is evaluated by a mathematical algorithm based on the data collected and integrated into the platform.~The ophthalmologist will fill in the ophthalmologist questionnaire in the platform with data on the fundus and blood pressure, after examining the patient.~The patient will fill in the lifestyle questionnaires (nutrition, smoking, gender, year of birth, level of education) with his personal equipment (computer, smartphone or tablet).
Study: NCT05282823

Intervention type: DEVICE
Intervention: Boston Scientific Cardiac Cryoablation System
Description: is indicated for cryoablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of AF as per current and future guidelines and system IFU/ Tenpubunsyo.
Study: NCT04638829

Intervention type: DRUG
Group type: OTHER
Intervention: Avatrombopag Oral Tablet
Description: Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information
Study: NCT06554587

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)
Description: Measurement of the plasma concentration of ST6GAL1, GCNT1 and GALNT7 biomarkers in patients suspected of having prostate cancer or on active surveillance
Study: NCT04946305

Intervention type: OTHER
Intervention: Lutathera
Description: Prospective observational study. There is no treatment allocation. Patients administered Lutathera by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT04848896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CORI Robotics
Description: Total knee arthroplasty (TKA) treated with CORI Robotics System.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Procedure
Description: Total knee arthroplasty (TKA) treated with conventional approach with conventional manual instrumentation.
Study: NCT05464758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated cold exposure
Description: 8 consecutive days of exposure to 8°C air for 120 minutes each day
Study: NCT04892420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The patients receive 20ml plain bupivacaine (0.5%) + 8 mg dexamethasone (2ml) in adductor canal block after spinal anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The patients receive 20 ml plain bupivacaine(0.5)+25 microgram dexmedetomidine( diluted in 2 ml normal saline) in adductor canal block after spinal anesthesia .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: The patients receive 20 ml plain bupivacaine(0.5)+200 milligram magnesium sulphate (2 ml of magnesium 10%) in adductor canal block after spinal anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: The patients receive 20ml plain bupivacaine (0.5%) + 2 ml of Normal saline in adductor canal block after spinal anesthesia.
Study: NCT05418608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiotracer
Description: A novel SV2A imaging tracer which is used in conjunction with positron emission tomography scans.
Study: NCT05543252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minzasolmin (UCB0599)
Description: Minzasolmin (UCB0599) Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive minzasolmin (UCB0599) in a pre-specified sequence during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minzasolmin (UCB0599)
Description: Minzasolmin (UCB0599) Pharmaceutical form: Granules in capsules Route of administration: Oral use Participants will receive minzasolmin (UCB0599) in a pre-specified sequence during the Treatment Period.
Study: NCT06418958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red Light
Description: Light Curing with Red Light

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue Light
Description: Light Curing with Blue Light
Study: NCT04779593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Sample Complete blood count
Description: Blood Sample Complete blood count at D0, M6, M12, M18 and M24/end follow-up visit

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample Iron panel
Description: Blood Sample Iron panel (serum ferritin, serum iron and serum transferrin to determine transferrin saturation according to randomization group (at M6, M12 and M18) at D0, M6, M12, M18 and M24/end follow-up visit and at each bloodletting.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Sample Iron panel
Description: Blood Sample Iron panel (serum ferritin, serum iron and serum transferrin to determine transferrin saturation according to randomization group (at M6, M12 and M18) at D0, M6, M12, M18 and M24/end follow-up visit and at each bloodletting.
Study: NCT04963764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Participants will be randomized to receive oral amoxicillin for a standard course (10 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to receive oral placebo for a standard course (10 days)
Study: NCT04779593

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood Sample Fasting Glucose
Description: Blood Sample Fasting Glucose at D0 and M24/end follow-up visit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood Sample Fasting Glucose
Description: Blood Sample Fasting Glucose at D0 and M24/end follow-up visit

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample lipid panel
Description: Blood sample lipid panel (total cholesterol, triglycerides, HDL, LDL) at D0 and M24/end follow-up visit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample lipid panel
Description: Blood sample lipid panel (total cholesterol, triglycerides, HDL, LDL) at D0 and M24/end follow-up visit

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample liver panel
Description: Blood sample liver panel (total bilirubin, Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma-Glutamyl Transferase) at D0 and M24/end follow-up visit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample liver panel
Description: Blood sample liver panel (total bilirubin, Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma-Glutamyl Transferase) at D0 and M24/end follow-up visit

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample C reactive protein
Description: Blood sample C reactive protein at D0 and M24/end follow-up visit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample C reactive protein
Description: Blood sample C reactive protein at D0 and M24/end follow-up visit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bloodletting - control group
Description: Patients treated with bloodletting according to current guidelines (ferritin alone). Patient will undergo bloodletting with a goal of maintaining a serum ferritin equal or lower than 50 g/L according to current clinical practice guidelines (French and European).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioBank
Description: Blood sample will be collected for BioBank at D0, M12 and M24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioBank
Description: Blood sample will be collected for BioBank at D0, M12 and M24.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medico-economical
Description: Medico-economic data will be collected at each follow up visit.
Study: NCT06442813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT GROUP
Description: One times one pregnancy
Study: NCT04603807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Entrectinib will be self-administered orally at a dose of 600 mg (three 200 mg capsules per day) once daily with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: Crizotinib will be self-administered orally at a dose of 250 mg twice daily with or without food.
Study: NCT04654325

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: conjunctival swab
Description: Patients will have conjunctival swab for SARS-CV-2 genome detection
Study: NCT04779593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medico-economical
Description: Medico-economic data will be collected at each follow up visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bloodletting - experimental group
Description: Patients treated with bloodletting according to transferrin saturation and serum ferritin. Patients will undergo bloodletting with a goal of maintaining a serum transferrin saturation equal or lower than 50 % and a serum ferritin lower than the upper limit of the normal range (300 g/L for men and 200 g/L for women).A first bloodletting will be performed at inclusion with the same volume as usually performed by the patients.Results of the biological test performed at this visit will guide the time schedule and volume of the next bloodletting according to randomization group. Time schedule and volume of bloodletting will be adjusted to biological results after each follow-up visit.
Study: NCT05672537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg intravenous injection for 21d cycle
Study: NCT04838392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIGHTEST Continuous Glucose Monitoring System
Description: RIGHTEST Continuous Glucose Monitoring System
Study: NCT05765656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GP - pharmacist collaboration and pharmacist motivational interviewing
Description: 1. Patients in the GP-CP clusters randomized to the intervention arm will be offered a joint GP-CP deprescribing intervention by their GP.~2. After the encounter, the patients will go to the pharmacy to get their medication dispensed. They will be given education materials. The pharmacist will plan with the patients 3 Motivational Interviews which will address the risks of using BZDR, and the benefits and modalities of stopping them. The pharmacists will receive a 2-day training course in MI. They will be given guidelines on BZDR deprescribing. If required, the pharmacists will be supported in their first MI.~3. Following each interview, the pharmacist will inform the GP by means of a formalized report of the points discussed. The pharmacist will inform the GP of the patient's choice or not to get involved in a deprescribing process and of the protocol followed. The objective of this exchange is to formalize the joint GP-CP intervention and to secure the deprescribing of BZDR.
Study: NCT04862858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: The educational intervention will involve guideline-based treatment recommendation information for providers via fax/mail and phone and provide resources via mail and phone for patients to learn more about ways to reduce their cardiovascular risk.
Study: NCT05415891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum
Description: The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with the study's community collaborative board, including representatives from the HIV care and advocacy communities as well as community members. The training is a whole-site training to address stigma as a barrier to accessing substance use and mental health services by persons living with HIV. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to persons living with HIV in order to reduce stigma-related barriers to mental health and substance use healthcare in Positive Impact Health Centers and increase retention in healthcare services for persons living with HIV.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: You℞ Decision prescribing platform
Description: The You℞ Decision prescribing platform is a mobile application that serves as a reference to quickly inform providers about the medications recommended for serious mental health disorders and naltrexone to treat AUD; the appropriate dosing regimen; and potential contraindications or interactions related to antiretroviral therapy medications or other psychiatric medication. Information for the platform is adapted from the Department of Veteran Affairs' Manual for HIV Care in Primary Care settings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: You℞ Decision prescribing platform
Description: The You℞ Decision prescribing platform is a mobile application that serves as a reference to quickly inform providers about the medications recommended for serious mental health disorders and naltrexone to treat AUD; the appropriate dosing regimen; and potential contraindications or interactions related to antiretroviral therapy medications or other psychiatric medication. Information for the platform is adapted from the Department of Veteran Affairs' Manual for HIV Care in Primary Care settings.
Study: NCT06185244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-supported internet-delivered trauma-focused CBT
Description: 12 weeks of therapist-supported internet-delivered trauma-focused CBT for both the youth and the care giver.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.
Description: 12 weeks of therapist-supported internet-delivered psychoeducation and stress management/relaxation for both the youth and the care giver.
Study: NCT05397444

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study with no intervention.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study with no intervention.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study with no intervention.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study with no intervention.
Study: NCT05471687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual-energy dual-layer spectral scanner
Description: Realization of dual-energy dual-layer spectral scanner with stress protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual-energy dual-layer spectral scanner
Description: Realization of dual-energy dual-layer spectral scanner with stress protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual-energy dual-layer spectral scanner
Description: Realization of dual-energy dual-layer spectral scanner with stress protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stress protocol with adenosin during dual-energy dual-layer spectral scanner
Description: Injection of intraveinous adenosin dose 0.78 mg/kg during dual-energy dual-layer spectral scanner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stress protocol with adenosin during dual-energy dual-layer spectral scanner
Description: Injection of intraveinous adenosin dose 0.78 mg/kg during dual-energy dual-layer spectral scanner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stress protocol with adenosin during dual-energy dual-layer spectral scanner
Description: Injection of intraveinous adenosin dose 0.78 mg/kg during dual-energy dual-layer spectral scanner
Study: NCT04364191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Behavioral Sleep Intervention for Insomnia
Description: The MBSI-I will include a meaningful activity protocol during the day and ART therapy at night.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The sleep hygiene educational material represents an active control intervention and is recommended as part of the initial treatment of insomnia based on an NIH guide for sleep education.
Study: NCT05672537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study: NCT04860349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: 4-weeks of high intensity interval training, 3 sessions/week on alternate days. each session for 20 minutes, excluding the warm-up and cool-down.
Study: NCT05672537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1000mg/m2, D1\&D8, 21d cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 25mg/m2, D1\&D8, 21d cycle.
Study: NCT06063369

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palmitoylethanolamide
Description: Dose: PEA 1200 mg given in 400 mg capsules (3 capsules per day) or Placebo Route of administration: oral Duration and frequency: study medication will be provided to patients in bottles every two weeks for the duration of the study (three dispensations).~Formulation: PEA and placebo in identical capsules. Dosing scheme: Patients will be instructed to take two capsules twice daily for the 42 days of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide
Description: Dose: PEA 1200 mg given in 400 mg capsules (3 capsules per day) or Placebo Route of administration: oral Duration and frequency: study medication will be provided to patients in bottles every two weeks for the duration of the study (three dispensations).~Formulation: PEA and placebo in identical capsules. Dosing scheme: Patients will be instructed to take two capsules twice daily for the 42 days of the study.
Study: NCT06418035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video modeling by scanning Qr code
Description: The protocol activity carried out by the experimental group will involve the use of the QR Code: in the operator's presence, the child scans the code through a technological device and watches the video of the activity to be played later in the HomeLab.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modeling traditional method
Description: The control group will carry out the protocol activities in a traditional way, without technological tools. The child observes the operator who shows the live activity inside the HomeLab.
Study: NCT05705804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 4 mg will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin plus Ezetemibe
Description: Pitvastatin 4 mg plus ezetemibe 10 mg will be given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40 mg will be given.
Study: NCT06070233

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: stereotactic radiosurgery (SRS) dorsal root rhizotomy radiomodulation
Description: Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing. Prescription dose is 50 Gy delivered in a single fraction to the target volume, prescribed to whatever isodose line produces optimal falloff (but not less than a 50% isodose line; dmax \<100Gy) .~All radiosurgery treatment will utilize the Varian Edge, Varian TrueBeam STx, or CyberKnife system

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients will be simulated in the supine position in an immobilization apparatus deemed by the treating physician to be appropriate for the patient being able to comfortably maintain position for the duration of treatment. All patients will be simulated and treated using free breathing.
Study: NCT06595342

Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study: NCT06504576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 MG Oral Tablet
Description: Two consecutive weeks of Cilostazol (50mg BID) two days after admission
Study: NCT05157789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS
Description: In the study, text message will be sent to relatives of the patients for informing and the effect will be determine on the level of anxiety during cardiovascular surgery.
Study: NCT06504576

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional internal medicine treatment
Description: Receives only conventional internal medicine treatment
Study: NCT04934319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance and Proprioceptive Training
Description: * Step-by-step training (5 levels)~* 30 minute per training~* 3 times per week~* Four weeks